Demographic, Payer, and Clinical Characteristics of Patients Receiving Bevacizumab (BEV) And Ranibizumab (RAN) For Treatment of Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME)
May 1, 2018, 00:00
10.1016/j.jval.2018.04.1641
https://www.valueinhealthjournal.com/article/S1098-3015(18)31963-6/fulltext
Title :
Demographic, Payer, and Clinical Characteristics of Patients Receiving Bevacizumab (BEV) And Ranibizumab (RAN) For Treatment of Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31963-6&doi=10.1016/j.jval.2018.04.1641
First page :
Section Title :
Open access? :
No
Section Order :
871